HLX-22
N/A
Report date: 2026/03/21 20:00:21
Base Information
Drug NameHLX-22
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[17]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAtlas Therapeutics AB
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesShanghai Fuhong Ruilin Biotechnology Co LtdAbclon IncGeneQuantum Healthcare (Suzhou) Co Ltd +[5]
Inactive CompaniesN/A
Active Indications +[5]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A